Sanofi India

June 9 (Reuters) - Sanofi India Ltd SANO.NS:

• SANOFI INDIA - TAX DEMAND OF 1.1 MILLION RUPEES AGAINST CO DROPPED

Source text: ID:nBSE3lcGlc

Further company coverage: SANO.NS

(([email protected];;))

** Sanofi India SANO.NS drops 3.5% to 3,990 rupees; on track for biggest single-day pct drop since September 26, 2025

** Drugmaker posts 32.4% y/y drop in quarterly profit; revenue falls 18.5% y/y

** Trading volumes at 84,190 shares - more than 7x the 30-day-avg

** YTD, SANO up 1.2%

(Reporting by Surbhi Misra in Bengaluru)

(([email protected] | X: https://twitter.com/SurbhiMisra_ |;))

Feb 25 (Reuters) - Sanofi India Ltd SANO.NS:

• RECOMMENDED FINAL DIVIDEND OF 48 RUPEES PER SHARE

• DEC-QUARTER PROFIT 617 MILLION RUPEES

• DEC-QUARTER REVENUE FROM OPERATIONS 4.2 BILLION RUPEES

Source text: ID:nBSE8sMtz7

Further company coverage: SANO.NS

(([email protected];;))

Feb 20 (Reuters) - Sanofi India Ltd SANO.NS:

• GETS TOTAL TAX DEMAND OF 23.7 MILLION RUPEES

Source text: ID:nBSE7z8Zlj

Further company coverage: SANO.NS

(([email protected];))

Feb 16 (Reuters) - Sanofi India Ltd SANO.NS:

• SANOFI HEALTHCARE INDIA- EXPANDS HYDERABAD GCC TO GROW CAPABILITIES AND DRIVE INNOVATION

• SANOFI INDIA- EXPANSION OF HYDERABAD GCC WOULD RESULT IN INCREASED CAPACITY TO HOST UP TO APPROX 4500 EMPLOYEES FROM EARLIER PROJECTED ABOUT 2600

Further company coverage: SANO.NS

(([email protected];))

Dec 30 (Reuters) - Sanofi India Ltd SANO.NS:

• GETS TAX DEMAND ORDER WORTH 14.3 MILLION RUPEES

Source text: ID:nBSEc12CBR

Further company coverage: SANO.NS

(([email protected];))

** Emcure Pharmaceuticals' EMCU.NS stock rises 2.2% to 1,333 rupees after BOB Capital initiates "buy" rating

** Brokerage sets 1,530 rupees PT, implying 20% upside on domestic recovery, Sanofi portfolio integration

** Says EMCU immune to U.S. tariff concerns after demerging American unit Avet Lifesciences, retains only Canada presence

** EMCU and Sanofi India announced distribution partnership in July to expand therapy portfolio

** BOB estimates cardiovascular therapy will become top contributor at 20.8% of sales post-integration vs gynecology previously

** Expects domestic sales boost from FY26-28 driven by portfolio expansion

** EMCU down 9.9% YTD vs Nifty 500's .NIFTY500 2.5% gain

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

** Shares of Sanofi India SANO.NS fall as much as 4.6% to 5,548 rupees, lowest since March 18

** Stock logs steepest intraday pct loss since January 13

** The drugmaker posts a 32.8% Y/Y decline in June-qtr profit; rev from ops drops 12.3% Y/Y

** Trading volume at nearly 14,324 shares so far, about 1.5x 30-day avg

** Stock down 9% YTD

(Reporting by Rudra Pratap Singh in Bengaluru)

(([email protected]))

July 31 (Reuters) - Sanofi India Ltd SANO.NS:

• SANOFI INDIA JUNE-QUARTER PROFIT 695 MILLION RUPEES

• SANOFI INDIA JUNE-QUARTER REVENUE FROM OPERATIONS 4.06 BILLION RUPEES

Source text: [ID:]

Further company coverage: SANO.NS

(([email protected];;))

** Analysts expect Indian drugmaker Dr Reddy's Laboratories REDY.NS to report near 14% rise in Q4 consol net PAT, rev to grow 18%, per data compiled by LSEG

** REDY's reported 2.3% rise in Q3 profit, and 36.5% in Q4 a year ago

** Jan-March qtr results to be helped by new drug launches in oncology and other chronic therapy areas, analysts say

** India business to see 15% YoY growth on incremental sales from acquired vaccine business from Sanofi India SANO.NS, says brokerage HDFC Securities

** Stock trading flat on the day vs 1.2% fall in the benchmark Nifty 50 index .NSEI

** REDY shares fell 17.6% in the Jan-March quarter, snapping eight straight quarterly gains, on Trump tariff woes

** REDY down ~2.6% this week, snapping three weeks of gains

** REDY among 8 stocks on 20-member pharma index rated "hold", rest, including rival Cipla CIPL.NS rated "buy" or higher- data compiled by LSEG

** REDY's down ~17% YTD while Nifty Pharma index .NIPHARM is down ~10.2%

($1 = 85.5200 Indian rupees)

(Reporting by Anuran Sadhu in Bengaluru)

(([email protected]; +91 8697274436;))

April 24 (Reuters) - Sanofi India Ltd SANO.NS:

• GETS TAX DEMAND ORDER FOR 52.6 MILLION RUPEES, PENALTY 52.6 MILLION RUPEES

Source text: ID:nBSE8R6nVX

Further company coverage: SANO.NS

(([email protected];;))

April 15 (Reuters) - Sanofi India Ltd SANO.NS:

• SANOFI INDIA - COMPANY HAS NO PLANS TO DIVEST, SELL OR LICENSE ITS BRAND LANTUS

• SANOFI INDIA - CLARIFICATION ON NEWS ARTICLE ON INSULIN BRAND LANTUS

Further company coverage: SANO.NS

(([email protected];))

April 9 (Reuters) - Sanofi India Ltd SANO.NS:

• RODOLFO HROSZ, MANAGING DIRECTOR RESIGNS

Source text: ID:nnAPN2QEZBF

Further company coverage: SANO.NS

(([email protected];;))

Feb 18 (Reuters) - Sanofi India Ltd SANO.NS:

• GETS ORDER FROM TAX DEPARTMENT UPHOLDING RECOVERY OF INTEREST AMOUNTING TO 10.1 MILLION RUPEES

Source text: ID:nBSE9YH6Hb

Further company coverage: SANO.NS

(([email protected];;))

** Shares of Emcure Pharmaceuticals EMCU.NS jump 5.8% to 1,387.9 rupees

** Kotak Institutional Equities upgrades rating on stock to "buy" from "add"; keeps fair value (FV) of 1,680 rupees, a 28% premium to last close - LSEG data

** Kotak's rating highest among three brokerages covering stock - LSEG

** Says co's organic growth expected to pick up more in H2 FY25, with upbeat prospects in countries including India, Canada

** Factors such as licensing deal with Sanofi India SANO.NS, EMCU expected to report 13% CAGR over FY24-27 - Kotak

** Expects Canada organic business to deliver 16% growth in H2 FY25 on benefits from partnership with Mantra Pharma

** EMCU eyes busiest day since early Oct, volumes at 3.7x the 30-day avg

** EMCU up ~5% since listing on July 10

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

Nov 7 (Reuters) - Sanofi India Ltd SANO.NS:

• SEPT-QUARTER CONSOL PROFIT 822 MILLION RUPEES

• SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 5.24 BILLION RUPEES

Source text: ID:nNSE8CLHJ0

Further company coverage: SANO.NS

(([email protected];;))

** Shares of Panacea Biotec PNCA.NS hit upper circuit of 5% at 349.79

** Co reached settlement with Sanofi Healthcare India in suit seeking to restrain Sanofi India's SANO.NS unit from marketing a fully liquid hexavalent vaccine

** SANO will not commercially launch the vaccine in India and withdraw oppositions to PNCA's patent, per the settlement

** SANO shares down 1.1%

** PNCA shares rose on Friday on getting loan to expand vaccine facility capacity

** Stock is on track to rise in eighth straight session if trend holds

** PNCA up ~99% YTD vs ~41% climb in SANO

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))

July 26 (Reuters) - Sanofi India Ltd SANO.NS:

• JUNE-QUARTER CONSOL PROFIT 1.03 BILLION RUPEES

• JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 4.64 BILLION RUPEES

Source text for Eikon: ID:nBSE558tlQ

Further company coverage: SANO.NS

(([email protected];))

By Rishika Sadam

HYDERABAD, July 17 (Reuters) - French drugmaker Sanofi SASY.PA plans to invest 400 million euros ($437.24 million) in its global capacity centre (GCC) in India by the end of the decade, as it aims to expand and more than double its workforce over the next two years, a top company executive said on Wednesday.

Sanofi will first invest 100 million euros ($109.31 million) by next year, Madeleine Roach, Executive Vice President, Business Operations, said at an event on Wednesday.

The GCC, an offshore facility in India's southern city of Hyderabad, is Sanofi's largest globally with an existing workforce of 1,000 employees. The company, which also makes vaccines, has GCCs in Budapest, Malaysia and Colombia.

The company aims to increase its strength to 2,600 by 2026, Roach told Reuters on the sidelines of the event.

This includes hiring data scientists and data engineers to grow its digital team and effectively use artificial intelligence tools.

"Hyderabad's Sanofi staff works very closely with stakeholders in the U.S. and France... the U.S. market has a lot of confidence in the capabilities here," said Roach.

The U.S. is Sanofi's largest market by revenue, according to the company.

The Hyderabad facility is expected to do a significant amount of documentation work related to drug clinical trials, Roach added.

Consulting firm EY estimates India's domestic GCC market size is expected to more than double to $110 billion by 2030, aided by a skilled workforce, and favourable business and policy environment.

In addition to the availability of talent in India, Roach also pointed to geopolitical factors for the company's focus on expanding in the country as pharma companies seek to limit their reliance on China.

($1 = 0.9148 euros)

(Reporting by Rishika Sadam in Hyderabad; Editing by Janane Venkatraman )

(([email protected];))

June 5 (Reuters) - Lupin Ltd LUPN.NS:

• COMPLETES ACQUISITION OF TWO BRANDS FROM SANOFI IN EUROPE AND CANADA

• ACQUISITION TO ENHANCE LUPIN'S RESPIRATORY BUSINESS IN GERMANY

• LUPIN ATLANTIS HOLDINGS SA COMPLETED ACQUISITION OF AARANETM IN GERMANY, NALCROMTM IN CANADA, NETHERLANDS

Source text for Eikon: ID:nBSE7x89N5

Further company coverage: LUPN.NS

(([email protected];))

** Shares of Sanofi India SANO.NS and Dr Reddy's Laboratories REDY.NS up 1.8% and 1.4%, respectively

** REDY, SANO partnered for distribution in India of SANO's vaccines

** SANO opened 3% higher before trimming some gains

** SANO closed 3.3% higher on Wednesday on distribution partnership with Cipla CIPL.NS; that was stock's best day since Feb. 19

** REDY and SANO among top gainers on Nifty Pharma index .NIPHARM, which is up 0.2%

** REDY on track for third straight weekly drop if trend holds; SANO on track to snap four straight weekly losses

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))

** Shares of Sanofi India SANO.NS and Cipla CIPL.NS up 2.8% and 0.6% respectively

** SANO, CIPL partnered for distribution in India of six SANO products used for central nervous system-related treatments

** SANO on track for best day since Feb. 19

** SANO top gainer on Nifty Pharma index .NIPHARM, which is swinging between gain and loss, last up 0.1%

** CIPL climbed for 13 straight weeks before easing 0.5% last week

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))

March 26 (Reuters) - Sanofi India Ltd SANO.NS:

• CO, CIPLA ANNOUNCE EXCLUSIVE DISTRIBUTION PARTNERSHIP TO EXPAND REACH OF CNS PORTFOLIO IN INDIA

• CIPLA WILL BE RESPONSIBLE FOR DISTRIBUTION OF SANOFI INDIA’S 6 CNS BRANDS

Further company coverage: SANO.NSCIPL.NS

(([email protected];))

March 13 (Reuters) - Sanofi India Ltd SANO.NS:

• CO AND EMCURE PHARMACEUTICALS ANNOUNCE EXCLUSIVE DISTRIBUTION PARTNERSHIP

Further company coverage: SANO.NS

(([email protected];))

Feb 23 (Reuters) - Sanofi India Ltd SANO.NS:

• RECOMMENDED A FINAL DIVIDEND OF 117 RUPEES PER SHARE

• DEC-QUARTER PROFIT 1.38 BILLION RUPEES VERSUS 1.31 BILLION RUPEES

• DEC-QUARTER REVENUE FROM OPERATIONS 6.94 BILLION RUPEES VERSUS 6.72 BILLION RUPEES

Further company coverage: SANO.NS

(([email protected];))

Feb 8 (Reuters) - Sanofi India Ltd SANO.NS:

• SANOFI INDIA LTD - 500674 - ANNOUNCEMENT UNDER REGULATION 30 (LODR)

• SANOFI INDIA LTD - DEMAND ORDER RECEIVED TOWARDS TAX PAYMENT OF 66.4 MILLION RUPEES UNDER TRANSFER PRICING ORDER

Source text for Eikon: ID:nBSE6WmCPg

Further company coverage: SANO.NS

(([email protected];))

Jan 3 (Reuters) - Sanofi India Ltd SANO.NS:

• GST ORDER PASSED RECOVERY OF 10.1 MILLION RUPEES

• SHALL FILE APPEAL AGAINST ORDER FOR PAYMENT OF INTEREST AND PENALTY

Further company coverage: SANO.NS

(([email protected];))

** India's pharmaceutical sector growth slowed to 2.9% year-on-year in November from 13.7% in October as volumes drop, data from All India Origin Chemists and Distributors (AIOCD) showed

** Volumes in November down 4.5% year-on-year after rising 5% in the previous month

** Dermatology and opthalmology segments witness fall in sales while anti-infectives, cardiac, respiratory segments see rise in sales in November

** Eris Lifesciences ERIS.NS, Cipla CIPL.NS, Torrent Pharmaceuticals TORP.NS, Sun Pharmaceutical Industries SUN.NS and Glenmark Pharmaceuticals GLEN.NS see sales uptick of 7% to 11%, outperforming the Indian pharma market

** FDC FDC.NS, Alembic Pharma ALEM.NS, GlaxoSmithKline Pharmaceuticals GLAX.NS and Mankind Pharma MNKI.NS underperform the industry, in terms of November sales

** Pfizer PFIZ.NS sees sales decline of 11.9% while Sanofi India SANO.NS posts 5.7% monthly sales drop

** Nifty pharma index .NIPHARM down 0.9% on the day, dragged by 5% drop in Dr. Reddy's Laboratories REDY.NS on U.S. drug regulator's observations on the drug maker's facility at Hyderabad

** Pharma index up 27% in 2023 so far, compared with 16% rise in Nifty 50 index .NSEI

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

** Shares of Indian drug maker Cipla CIPL.NS rise as much as 2.4% to a record 1,283.55 rupees

** Stock has added 9% since reporting strong Q2 results on Oct. 30 and has since gained in 11 of the 16 sessions

** Pharma index .NIPHARM up 1% Wednesday, led by gains in CIPL, Natco Pharma NATP.NS, GlaxoSmithKline PharmaGLAX.NS, Sanofi SANO.NS among others

** CIPL up 18% YTD, underperforming 28% gains in pharma index

(Reporting by Sethuraman NR)

(([email protected]; (+91 9945291420); Reuters Messaging: [email protected]))

Nov 8 (Reuters) - Sanofi India Ltd SANO.NS:

• SANOFI INDIA LTD - 500674 - BOARD MEETING OUTCOME FOR UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 30TH SEPTEMBER 2023

• SANOFI INDIA LTD SEPT-QUARTER PROFIT 1.52 BILLION RUPEES VERSUS 1.31 BILLION RUPEES

• SANOFI INDIA LTD SEPT-QUARTER REVENUE FROM OPERATIONS 7.15 BILLION RUPEES VERSUS 6.92 BILLION RUPEES

Source text for Eikon: ID:nBSE1R0Pwg

Further company coverage: SANO.NS

(([email protected];))